CA2306995A1 - Compositions and methods for systemic delivery of oral vaccines and therapeutic agents - Google Patents

Compositions and methods for systemic delivery of oral vaccines and therapeutic agents Download PDF

Info

Publication number
CA2306995A1
CA2306995A1 CA002306995A CA2306995A CA2306995A1 CA 2306995 A1 CA2306995 A1 CA 2306995A1 CA 002306995 A CA002306995 A CA 002306995A CA 2306995 A CA2306995 A CA 2306995A CA 2306995 A1 CA2306995 A1 CA 2306995A1
Authority
CA
Canada
Prior art keywords
asn
ile
ser
leu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002306995A
Other languages
English (en)
French (fr)
Inventor
Lance Simpson
Nikita Kiyatkin
Andrew Maksymowych
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2306995A1 publication Critical patent/CA2306995A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002306995A 1997-10-20 1998-10-16 Compositions and methods for systemic delivery of oral vaccines and therapeutic agents Abandoned CA2306995A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/954,302 1997-10-20
US08/954,302 US6051239A (en) 1997-10-20 1997-10-20 Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
PCT/US1998/021897 WO1999020306A1 (en) 1997-10-20 1998-10-16 Compositions and methods for systemic delivery of oral vaccines and therapeutic agents

Publications (1)

Publication Number Publication Date
CA2306995A1 true CA2306995A1 (en) 1999-04-29

Family

ID=25495232

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002306995A Abandoned CA2306995A1 (en) 1997-10-20 1998-10-16 Compositions and methods for systemic delivery of oral vaccines and therapeutic agents

Country Status (16)

Country Link
US (1) US6051239A (https=)
EP (1) EP1024827B1 (https=)
JP (1) JP2001522783A (https=)
KR (1) KR100594787B1 (https=)
CN (1) CN1246038C (https=)
AT (1) ATE355076T1 (https=)
AU (1) AU756475B2 (https=)
BR (1) BR9815255A (https=)
CA (1) CA2306995A1 (https=)
DE (1) DE69837209T2 (https=)
EE (1) EE200000536A (https=)
HU (1) HUP0101017A3 (https=)
IL (1) IL135743A (https=)
NZ (1) NZ504549A (https=)
RU (1) RU2227042C2 (https=)
WO (1) WO1999020306A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227010B2 (en) 1993-09-21 2007-06-05 United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
DK1398038T4 (da) * 2000-02-08 2011-03-28 Allergan Inc Lægemidler med botulinustoxin
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
CA2428270C (en) * 2000-11-06 2013-07-02 Leonard A. Smith Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
JP4707254B2 (ja) * 2001-04-24 2011-06-22 クミアイ化学工業株式会社 粒状組成物及びその製造方法
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
EP1531859A4 (en) * 2002-05-31 2005-12-07 Univ Jefferson COMPOSITIONS AND METHODS FOR TRANSEPITHELIAL MOLECULAR TRANSPORT
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
WO2004044161A2 (en) 2002-11-06 2004-05-27 Fraunhofer Usa Expression of foreign sequences in plants using trans-activation system
US7683238B2 (en) * 2002-11-12 2010-03-23 iBio, Inc. and Fraunhofer USA, Inc. Production of pharmaceutically active proteins in sprouted seedlings
US7692063B2 (en) * 2002-11-12 2010-04-06 Ibio, Inc. Production of foreign nucleic acids and polypeptides in sprout systems
KR20050094817A (ko) * 2002-12-20 2005-09-28 보툴리늄 톡신 리서치 어쏘시에이츠, 인크. 개선된 약제학적 보툴리늄 독소 조성물
ES2531125T3 (es) 2003-02-03 2015-03-10 Ibio Inc Sistema para la expresión de genes en plantas
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
EP1769068B1 (en) * 2004-02-20 2014-12-31 iBio, Inc. Systems and methods for clonal expression in plants
US7306807B2 (en) 2004-09-13 2007-12-11 Wyeth Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease
WO2006068794A2 (en) * 2004-11-22 2006-06-29 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
EP1931379B1 (en) 2005-10-07 2013-05-29 Health Protection Agency Proteins with improved solubility and methods for producing and using same
ME00485B (me) 2005-10-07 2011-10-10 Zoetis Services Llc VAKCINE l METODE LIJEČENJA INFLUENCE KOD CANINA
US20080299149A1 (en) * 2007-05-30 2008-12-04 Wyeth Raccoon Poxvirus Expressing Genes of Feline Antigens
US8445650B2 (en) * 2007-09-25 2013-05-21 Thomas Jefferson University Mutant botulinum neurotoxin serotype A polypeptide and uses thereof
WO2010096134A1 (en) 2008-12-04 2010-08-26 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
US9315549B2 (en) 2013-01-28 2016-04-19 New York University Treatment methods using atoxic neurotoxin derivatives
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11897921B2 (en) 2014-12-09 2024-02-13 New York University Propeptide fusion comprising a mutated clostridium botulinum neurotoxin and a VHH domain
AU2018389104A1 (en) 2017-12-20 2020-07-30 Allergan, Inc. Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
JP3523879B2 (ja) * 1994-05-31 2004-04-26 アレルガン インコーポレイテッド 輸送タンパク質用クロストリジウム属細菌毒素の修飾
NZ295998A (en) * 1994-10-24 1999-10-28 Ophidian Pharm Inc Neutralizing antitoxins against clostridium difficile and clostidium botulinum toxins
WO1996040229A1 (en) * 1995-06-07 1996-12-19 Thomas Jefferson University Vaccines synthesized by transgenic plants
AU6326896A (en) * 1996-03-08 1997-09-22 Regents Of The University Of California, The Chemically-modified clostridiatoxin with improved properties

Also Published As

Publication number Publication date
EP1024827B1 (en) 2007-02-28
EE200000536A (et) 2002-04-15
IL135743A (en) 2004-03-28
NZ504549A (en) 2002-12-20
EP1024827A4 (en) 2002-08-28
AU756475B2 (en) 2003-01-16
AU1094799A (en) 1999-05-10
JP2001522783A (ja) 2001-11-20
HUP0101017A2 (hu) 2001-07-30
DE69837209D1 (de) 2007-04-12
HUP0101017A3 (en) 2003-11-28
EP1024827A1 (en) 2000-08-09
KR20010031236A (ko) 2001-04-16
CN1246038C (zh) 2006-03-22
DE69837209T2 (de) 2007-10-31
IL135743A0 (en) 2001-05-20
ATE355076T1 (de) 2006-03-15
BR9815255A (pt) 2001-12-26
WO1999020306A1 (en) 1999-04-29
RU2227042C2 (ru) 2004-04-20
CN1290174A (zh) 2001-04-04
US6051239A (en) 2000-04-18
KR100594787B1 (ko) 2006-07-03

Similar Documents

Publication Publication Date Title
AU756475B2 (en) Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
Kiyatkin et al. Induction of an immune response by oral administration of recombinant botulinum toxin
JP3927233B2 (ja) 肺炎双球菌感染症に対する免疫化のための肺炎双球菌多糖−組み換えニューモリシン結合体ワクチン類
DE69332434T2 (de) Clostridium perfringens Impfstoffe
US8012479B2 (en) Recombinant toxin fragments
US20040247617A1 (en) Fusion antigen used as vaccine
JP2002541808A (ja) ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
CA2365915C (en) Recombinant toxin a/toxin b vaccine against clostridium difficile
CA2592627C (en) Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide
NZ220027A (en) Antigens or haptens coupled to escherichia coli outer membrane proteins for enhancement of immune response
US6733760B1 (en) Recombinant toxin A/toxin B vaccine against Clostridium difficile
KR101130884B1 (ko) 패혈증 비브리오균의 플라젤린과 병원체의 항원 단백질을 융합시켜 제조한 재조합 융합 단백질 및 이를 유효성분으로 포함하는 점막 투여용 백신
US5955080A (en) Self-adjuvanting peptide vaccine delivery system and production thereof
US6287566B1 (en) Protective peptides neurotoxin of C. botulinum
JP2790333B2 (ja) 外来プロモーターおよび／またはリーダーペプチドを用いたコレラトキシンｂサブユニットの組換え発現系
JP2002514061A (ja) 肺炎球菌ｄｎａを投与するための組成物および方法
Mustafa et al. Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge
EP1090994A2 (en) Peptide repeat immunogens
CA2298558A1 (en) Genetically engineered rhodococcus vaccine
US20030185850A1 (en) Protective peptides neurotoxin of C. botulinum
CZ20001399A3 (cs) Prostředky a způsoby pro systémové podání orálních vakcín a terapeutických činidel
MXPA00003799A (en) Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
JP2004529601A (ja) 組換えインフルエンザ菌アドヘシンタンパク質
WO2025257397A1 (en) Live attenuated bordetella vaccines capable of producing and secreting heterologous antigens
Joubert Expression of the botulinum neurotoxin serotype D binding domain in Brevibacillus brevis and its evaluation as a candidate vaccine antigen in mice

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued